NVIDIA Pushes AI Into Drug Development With Simulations Plus Collaboration

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

• NVIDIA (NasdaqGS:NVDA) has entered a new collaboration with Simulations Plus to apply GPU acceleration and AI-assisted workflows to drug development and quantitative systems pharmacology.

• The partnership focuses on speeding up complex modeling and simulation tasks that support earlier stage drug discovery and development decisions.

• This move extends NVIDIA’s reach further into life sciences, complementing its existing presence in broader AI and data center computing.

NVIDIA, with a recent share price of $211.497, has seen very large 3 year and 5 year returns, alongside an 80.2% return over the past year. In the shorter term, the stock is up 6.0% over the past week, 18.8% over 30 days, and 12.0% year to date, which keeps investor attention high as the company pursues new verticals such as pharmaceutical research.

For readers tracking how AI moves closer to real world applications, this Simulations Plus collaboration shows NVIDIA pushing its GPUs and software into workflows that sit at the core of drug R&D. Investors who follow NasdaqGS:NVDA may watch how deeply its platforms become embedded in areas such as quantitative systems pharmacology and whether similar partnerships emerge across the broader life sciences sector.

Stay updated on the most important news stories for NVIDIA by adding it to your watchlist or portfolio. Alternatively, explore our…